Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12791705 | 0.95 | L3MBTL1 (0.34) | HDAC4ALDH1A1L3MBTL1POLBCASP3 | |
| SCHEMBL16662276 | 0.93 | L3MBTL1 (0.37) | HDAC4ALDH1A1L3MBTL1POLBCASP3 | |
| SCHEMBL587475 | 0.90 | HDAC4 (0.38) | HDAC4KDM4E | |
| SCHEMBL19582822 | 0.80 | OPRL1 (0.41) | — | |
| SCHEMBL31127615 | 0.80 | HRH3 (0.41) | — | |
| SCHEMBL24755952 | 0.76 | TDO2 (0.36) | HDAC4L3MBTL1KDM4E | |
| SCHEMBL12457538 | 0.76 | MAPK1 (0.37) | L3MBTL1 | |
| SCHEMBL11227546 | 0.76 | ESR2 (0.35) | HDAC4L3MBTL1KDM4E | |
| SCHEMBL2677934 | 0.76 | CHRNB4 (0.40) | KDM4E | |
| SCHEMBL23388445 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021144287-A1 | 3-BENZOYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS MKK4 INHIBITORS FOR TREATING LIVER DISEASES | HEPAREGENIX GMBH (DE) | 2021-07-22 | — | — | WO | disclosed |
| EP-3080113-B1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-09-18 | — | — | EP | disclosed |
| US-10087179-B2 | Fused tricyclic imidazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-10-02 | — | — | US | disclosed |
| US-20160376268-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | SANOFI (FR) | 2016-12-29 | — | — | US | disclosed |
| EP-3080113-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| CN-105814049-A | Fused tricyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2016-07-27 | — | — | CN | disclosed |
| WO-2015086526-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| EP-1831199-B1 | MMP inhibitors | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-20100256166-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-07 | — | — | US | disclosed |
| US-7655664-B2 | Hydantoin derivatives as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| CN-101119987-A | Novel compounds | ASTRAZENECA AB GABOS BALINT (SE) | 2008-02-06 | — | — | CN | disclosed |
| EP-1831199-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065215-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376268-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | HDAC4 611/4885ALDH1A1 1999/4885L3MBTL1 2749/4885 |
| US-20100256166-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | HDAC4 463/4885ALDH1A1 169/4885L3MBTL1 3397/4885 |
| US-10087179-B2 | Fused tricyclic imidazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | HDAC4 611/4885ALDH1A1 1999/4885L3MBTL1 2749/4885 |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | HDAC4 463/4885ALDH1A1 169/4885L3MBTL1 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.